Assessing real world dose adjustment in patients switching from intravenous immunoglobulin (IGIV) therapy to subcutaneous immunoglobulin (IGSC) 20%.

被引：0
|
作者：
Ye, Xiaolan [1 ]
Xiong, Yan [2 ]
Li-McLeod, Josephine [2 ]
机构：
[1] Baxter HealthCare, Deerfield, IL USA
[2] Baxter HealthCare, Westlake Village, CA USA
来源：
PHARMACOTHERAPY | 2014年 / 34卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
177
引用
收藏
页码：E222 / E222
页数：1
相关论文
共 50 条
  • [1] Assessing Real World Dose Adjustment in Patients Switching from Intravenous Immunoglobulin (IGIV) Therapy to Subcutaneous Immunoglobulin (IGSC) 20%
    Luo, Michelle
    Iyer, Ravi
    Xiong, Yan
    Li-McLeod, Josephine
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 392 - 392
  • [2] Assessment of Actual Dose Adjustment in Patients Switching From Intravenous Immunoglobulin (IGIV) Therapy to IGSC 20%
    Luo, M.
    Iyer, R.
    Li-McLeod, J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB110 - AB110
  • [3] Estimated Impact on Drug Utilization and Costs Associated with Switching from Intravenous Immunoglobulin (IGIV) Therapy to Subcutaneous Immunoglobulin (IGSC) 20% Therapy
    Luo, Michelle
    Iyer, Ravi
    Li-McLeod, Josephine
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 399 - 399
  • [4] EVIDENCE OF ACTUAL DOSE ADJUSTMENT IN PATIENTS SWITCHING FROM INTRAVENOUS IMMUNOGLOBULIN (IGIV) THERAPY TO IGSC 20%: A STUDY OF THREE US SPECIALTY PHARMACY DATABASES
    Luo, M.
    Iyer, R.
    Xiong, Y.
    Li-McLeod, J.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 164 - 165
  • [5] Switching From Intravenous Immunoglobulin (IGIV) Therapy to IGSC 20%: Estimated Impact on Dosing Requirements and Cost of Therapy
    Iyer, R.
    Luo, M.
    Li-McLeod, J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB109 - AB109
  • [6] Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
    Krishnarajah, Girishanthy
    Lehmann, Jee-Yeon K.
    Ellman, Brian
    Bhak, Rachel H.
    DerSarkissian, Maral
    Leader, Deane, Jr.
    Bullinger, Ann L.
    Duh, Mei Sheng
    AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 (15): : S475 - S481
  • [7] Efficacy and Safety of IgPro20, a 20% Immunoglobulin for Subcutaneous Administration, in Patients with Primary Immunodeficiency Switching from Intravenous Replacement Therapy
    Jolles, Stephen
    Cristea, Victor
    Wahn, Volker
    Debre, Marianne
    Longhurst, Hilary
    Zenker, Othmar
    Peter, Hans-Hartmut
    Borte, Michael
    CLINICAL IMMUNOLOGY, 2010, 135 : S86 - S87
  • [8] Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
    Canessa, Clementina
    Iacopelli, Jessica
    Pecoraro, Antonio
    Spadaro, Giuseppe
    Matucci, Andrea
    Milito, Cinzia
    Vultaggio, Alessandra
    Agostini, Carlo
    Cinetto, Francesco
    Danieli, Maria Giovanna
    Gambini, Simona
    Marasco, Carolina
    Trizzino, Antonino
    Vacca, Angelo
    De Mattia, Domenico
    Martire, Baldassarre
    Plebani, Alessandro
    Di Gioacchino, Mario
    Gatta, Alessia
    Finocchi, Andrea
    Licciardi, Francesco
    Martino, Silvana
    De Carli, Marco
    Moschese, Viviana
    Azzari, Chiara
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2017, 30 (01) : 73 - 82
  • [9] What Factors Influence Patients' Decisions To Stop Subcutaneous Immunoglobulin Therapy And Return To Intravenous Immunoglobulin Therapy?
    Graham, Emma
    Symons, Christine
    Trump, Teddie
    Leeman, Lucy
    Whyte, Andrew
    Bethune, Claire
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 182 : 13 - 14
  • [10] Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
    Kevin Rosenbach
    Michelle Park
    Marie Sanchirico
    Oliseyenum Nwose
    Kenneth Paris
    Journal of Clinical Immunology, 2023, 43 (5) : 912 - 920
12345